Kymera CEO exercises options, sells 30K shares

Kymera Therapeutics CEO Nello Mainolfi reported a combination of option exercises and share sales on 2026-02-25.

Rhea-AI Filing Summary

Kymera Therapeutics CEO Nello Mainolfi reported a combination of option exercises and share sales on 2026-02-25. He exercised stock options for 30,000 shares at an exercise price of $2.08 per share, converting a derivative award into common stock.

On the same day he sold a total of 30,000 shares of common stock in open-market transactions at weighted average prices within disclosed ranges between $89.16 and $93.15 per share, pursuant to a pre-established Rule 10b5-1 trading plan dated September 6, 2024. After these transactions, he directly owned 666,195 shares of Kymera common stock.

Insider Trade Summary

Exercise and Sale: 30,000 shares ($2.65M approx. pre-tax spread)

Exercise and Sale 7 txns

Insider Mainolfi Nello

Role Chief Executive Officer

Sold 30,000 shs ($2.71M)

Approx. gross sale proceeds $2.71M

Approx. exercise cost $62K

Approx. pre-tax spread $2.65M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	30,000	$0.00	$0.00
Exercise	Common Stock	30,000	$2.08	$62K
Sale	Common Stock	19,764	$89.78	$1.77M
Sale	Common Stock	5,434	$90.39	$491K
Sale	Common Stock	3,293	$91.76	$302K
Sale	Common Stock	1,501	$92.81	$139K
Sale	Common Stock	8	$93.49	$747.92

Holdings After Transaction: Stock Option (Right to Buy) — 245,559 contracts (Direct); Common Stock — 666,195 shares (Direct)

Footnotes (6)

1. F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.16 to $90.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.16 to $90.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.295 to $92.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.20 to $93.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
6. F6. The shares underlying this stock option are fully vested and exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kymera (KYMR) CEO Nello Mainolfi report in this Form 4?

Nello Mainolfi reported exercising options and selling shares of Kymera common stock. He exercised stock options for 30,000 shares and sold 30,000 shares in open-market trades, all on February 25, 2026, under a pre-set Rule 10b5-1 trading plan.

How many Kymera (KYMR) shares did the CEO sell, and at what prices?

The CEO sold 30,000 Kymera common shares in multiple open-market transactions. The filing states weighted average prices, with sales occurring in ranges between $89.16 and $93.15 per share, as detailed across several footnotes describing the different trading price intervals.

What stock option activity did Kymera (KYMR) disclose for its CEO?

Kymera disclosed that its CEO exercised stock options covering 30,000 shares of common stock. These options had an exercise price of $2.08 per share, were fully vested and exercisable, and the exercise converted the derivative award into directly held Kymera common shares on February 25, 2026.

Was the Kymera (KYMR) CEO’s stock sale part of a trading plan?

Yes, the filing states the transactions were made under a Rule 10b5-1 trading plan. This plan was adopted on September 6, 2024, allowing pre-arranged trades to execute automatically, which can help separate personal trading decisions from day-to-day corporate developments.

How many Kymera (KYMR) shares does the CEO hold after these transactions?

After completing the option exercise and related sales, the CEO directly owned 666,195 Kymera common shares. This post-transaction ownership figure reflects all reported moves on February 25, 2026, including both the derivative option exercise and the subsequent open-market sales.

What do the weighted average price footnotes mean in the Kymera (KYMR) Form 4?

The footnotes explain that reported sale prices are weighted averages across multiple trades. Individual shares were sold in separate transactions within specified ranges, such as $89.16–$90.14 or $92.20–$93.15, and detailed trade-by-trade pricing is available upon request from the CEO or issuer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/25/2026 - 05:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mainolfi Nello

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/25/2026		M(1)		30,000	A	$2.08	696,195	D
Common Stock	02/25/2026		S(1)		19,764	D	$89.78(2)	676,431	D
Common Stock	02/25/2026		S(1)		5,434	D	$90.39(3)	670,997	D
Common Stock	02/25/2026		S(1)		3,293	D	$91.76(4)	667,704	D
Common Stock	02/25/2026		S(1)		1,501	D	$92.81(5)	666,203	D
Common Stock	02/25/2026		S(1)		8	D	$93.49	666,195	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.08	02/25/2026		M(1)			30,000	(6)	11/13/2029	Common Stock	30,000	$0	245,559	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.16 to $90.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.16 to $90.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.295 to $92.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.20 to $93.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The shares underlying this stock option are fully vested and exercisable.

	/s/ Bruce Jacobs, as Attorney-in-Fact	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.